Will delays from the coronavirus pandemic affect localised prostate cancer outcomes?

Sean Ong1,2, Dominic Bagguley1,2, Declan Murphy1,2, Nathan Lawrentschuk1,2,3

1E.J. Whitten Foundation Prostate Cancer Research Centre at Epworth, Epworth HealthCare, Melbourne, Australia
2Department of Urology, Peter MacCallum Cancer Centre, Melbourne, Australia
3Department of Urology, Royal Melbourne Hospital, Melbourne, Australia

Introduction

• The global coronavirus (COVID-19) pandemic presents a unique situation whereby governing bodies seek to balance the risks of deferring treatment with the preservation of hospital resources.

• For the moment, there are no widely accepted “COVID-19 era” management guidelines for patients with prostate cancer.

• Many difficult decisions need to be made on a case by case basis, bearing in mind hospital capabilities, disease risk, patient factors and of course patients’ mental health and anxiety.

Aims

To review the evidence for the safety of delayed radical prostatectomies and explore the role of androgen deprivation therapy (ADT) in this unprecedented situation

Methodology

• Important topics relating to the review were identified.
• Google scholar, PubMed and Cochrane library were then searched to identify evidence suited to the topics.
• Key words “prostate”, “prostate cancer”, “radical prostatectomy”, “neoadjuvant therapy” were used to standardise the search amongst the search engines. The search included but was not limited to these key words.

References


The authors would like to acknowledge the ongoing funding support of both the EJ Whitten Foundation Prostate Cancer Research Centre and The Epworth Medical Foundation.